Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar <scp>Insulin‐R</scp> with the <scp>US</scp> ‐licensed <scp>Humulin® R</scp> formulation in healthy subjects: Results from the <scp>RHINE</scp> ‐1 ( <scp>Recombinant Human INsulin Equivalence‐1</scp> ) study-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US ‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE ‐1 ( Recombinant Human INsulin Equivalence‐1 ) study

Published:2022-01-28 Issue:4 Volume:24 Page:713-721
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Plum‐Mörschel Leona¹,Singh Gursharan²^ORCID,Murugesan Sundara Moorthi Nainar²,Marwah Ashwani²,Panda Jayanti²,Loganathan Subramanian²,Athalye Sandeep N.²

Affiliation:

1. Profil Mainz Germany

2. Biocon Biologics Ltd. Bengaluru India

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14635

Reference34 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

2. Insulin Access and Affordability Working Group: Conclusions and Recommendations

3. World Health Organization.WHO launches first‐ever insulin prequalification programme to expand access to life‐saving treatment for diabetes 2019.https://www.who.int/news/item/13-11-2019-who-launches-first-ever-insulin-prequalification-programme-to-expand-access-to-life-saving-treatment-for-diabetes. Accessed December 2 2021.

4. Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases

5. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure;Clinical Pharmacology in Drug Development;2024-03-21

2. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE‐2 (Recombinant Human INsulin Equivalence‐2) study;Diabetes, Obesity and Metabolism;2023-02-14

3. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2023-02-01

4. How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers;Frontiers in Pharmacology;2022-07-22

5. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study;Diabetes, Obesity and Metabolism;2022-06-06